Bruesewitz v. Wyeth LLC
The Court ruled that a federal vaccine-injury law bars parents from suing vaccine manufacturers in state court over claims that a vaccine's design was defective, even when a child suffers serious harm.
The decision means families seeking compensation for vaccine-related design problems must rely entirely on the federal no-fault compensation program rather than traditional lawsuits, cementing a nationwide legal shield for an industry Congress worried could collapse under tort litigation.
“The language of the provision thus suggests that the design of the vaccine is a given, not subject to question in the tort action.”
The majority's core reasoning that vaccine design cannot be challenged in lawsuits under the statute.
How it got here: A federal trial court granted the manufacturer summary judgment on preemption grounds; the Third Circuit affirmed; the family asked the Supreme Court to review that ruling.
The Case in Depth
What happened
Hannah Bruesewitz suffered severe seizures within a day of receiving a DTP vaccine as an infant in 1992, and was later diagnosed with a seizure disorder and developmental delay. Her parents first sought compensation through the federal vaccine injury program, then, after losing there, sued the vaccine's manufacturer (later purchased by Wyeth) in Pennsylvania state court, arguing the vaccine's design was defective.
The question before the Court
Does the federal law shielding vaccine makers from lawsuits over "unavoidable" side effects also block claims that a vaccine should have been designed more safely?
Why it matters
Parents of vaccine-injured children can no longer sue manufacturers in court over a vaccine's design, even if a safer design might have existed. They must instead seek compensation through the federal no-fault program. Vaccine makers gain significant protection from a major category of lawsuits, which Congress intended to help stabilize the vaccine supply.
What changes now
This is a final merits ruling, so the underlying preemption question is settled nationwide: state-law design-defect claims against vaccine manufacturers covered by the federal vaccine injury program cannot proceed in court. Families with similar design-defect claims must instead seek relief through the federal no-fault vaccine compensation program. The ruling does not affect claims based on improper manufacturing or inadequate warnings, which can still go forward under narrower conditions.
What this does not decide
The ruling addresses only design-defect claims against covered vaccines under this particular statute. It does not affect lawsuits based on improper manufacturing or inadequate warnings, which remain available under narrower circumstances, and it does not decide broader questions about vaccine safety science or the compensation program's adequacy.
Concurrences and dissents
Concurrence — Justice Breyer
Justice Breyer agreed with the majority's reading of the text but thought the textual question alone was close, so he also examined legislative history, the statute's purpose, and the views of federal health regulators. He concluded all of these additional sources reinforced the majority's conclusion that design-defect suits are barred, giving significant weight to the expert judgment of health regulators over juries.
Dissent — Justice Sotomayor
“In doing so, the Court excises 13 words from the statutory text, misconstrues the Act's legislative history, and disturbs the careful balance Congress struck between compensating vaccine-injured children and stabilizing the childhood vaccine market.”The dissent's central objection that the majority's reading ignores key statutory language.
Justice Sotomayor argued the majority's reading effectively deletes 13 words from the statute and ignores that the law's conditional 'if' language shows Congress meant a case-by-case inquiry into whether a vaccine's design was truly unavoidable, not a blanket exemption. She argued the legislative history, including a 1987 committee report, confirms design-defect suits were meant to survive, and warned the ruling leaves no one accountable for ensuring vaccine designs keep pace with science.
How the Court got there
The legal reasoning, step by step
- The Court focused on the statute's specific wording: manufacturers are shielded from liability for side effects that were 'unavoidable' 'even though' the vaccine was properly made and properly labeled. The Court read this to mean that once a vaccine is properly manufactured and labeled, any remaining side effects — including those caused by the vaccine's design — count as unavoidable by law, so the design itself cannot be challenged in a lawsuit.
- The Court applied the interpretive principle of 'expressio unius, exclusio alterius' — the idea that naming some items in a list implies the exclusion of others not named. Because the statute specifically excused manufacturing and labeling defects but never mentioned design defects, the Court concluded Congress deliberately chose not to preserve design-defect lawsuits.
- The Court rejected the argument that 'unavoidable' was a specialized legal term borrowed from a products-liability treatise (comment k to the Restatement of Torts), finding no textual signal that Congress meant to import that treatise's case-by-case test rather than use the word in its ordinary sense.
- The Court looked at the surrounding regulatory structure, noting that federal rules extensively regulate vaccine manufacturing and labeling but never address vaccine design, and reasoned that this asymmetry confirms design was deliberately left out of the liability scheme.
- The Court reasoned that the law's own tools — a federally funded compensation program and federal programs to improve vaccine design — already serve the two purposes that design-defect lawsuits normally serve (compensating injured people and encouraging safer designs), so preempting design suits did not leave those goals unaddressed.